EGFR and neoplasm: found that the combination of cetuximab and oncolytic herpes simplex virus canerpaturev (C‐REV) exerted a stronger antitumor effect by promoting the distribution of C‐REV in the tumor and inhibiting angiogenesis than either of them alone.[407] Given that EGFR is expressed or amplified in many cancers, equipping oncolytic viruses with EGFR‐redirection paramyxavirus glycoprotein H/F complex can enhance the targeting ability of oncolytic viruses.